.jpg)
Oops! Something went wrong while submitting the form.
GLP-1 receptor agonists — semaglutide, tirzepatide and related agents — were developed for type 2 diabetes and have substantial evidence in that indication. They are also now used for weight management in obesity-related conditions where standard approaches have not produced adequate change, and increasingly for related cardiovascular risk reduction. The clinical evidence in their primary indications is strong; the broader cultural conversation around them is noisier.
GLP-1 medications in this pathway are prescribed inside a clinical assessment, against defined indications, with structured monitoring. The work is not weight-loss prescribing as a default. It is the careful use of a class of medications that, where indicated, can change the metabolic picture meaningfully — and where not, should not be used.
Side-effects matter. GLP-1s slow gastric emptying as part of their mechanism; this is part of why they reduce appetite, and it is also why they can worsen pictures where gastric motility is already slow (gastroparesis, dysautonomia with motility involvement, mast-cell-related GI symptoms). Nausea is common at initiation and titration. The medications often need to be continued long-term to maintain effect, and rebound is common when stopped without a plan. Each of these is part of the conversation before prescribing.
This service is for adults with type 2 diabetes, metabolic syndrome, or obesity-related conditions where GLP-1 prescription is clinically indicated and where structured monitoring is available. It is not appropriate for everyone seeking weight loss, and it is not used outside its clinical indications.
The first appointment reads the full picture. Metabolic context, prior treatments, current medications, gastrointestinal function, prior pancreatitis or thyroid history, current symptoms. The question being asked is whether GLP-1 is the right tool for this picture, not whether the patient wants it.
Where GLP-1 is appropriate, what is reasonable to expect — and what is not — is discussed before prescribing. Side-effects, contraindications, the long-term picture (including what stopping the medication may look like), and the cost and access context are all named openly.
The medication is started at a low dose with slow titration. In bodies with already-slow gastric motility — dysautonomia, MCAS-related GI involvement, history of gastroparesis — titration is slower again and tolerance is monitored more carefully.
Weight, metabolic markers, gastrointestinal tolerance, broader symptoms and any side-effects are tracked across the trial. The biio. record holds what was tried and what response followed.
The plan is built with the rest of the biio. team in view. Where dysautonomia, mast-cell or other GI-sensitive pictures overlap, those are read into the prescribing decision. Where shared care with the patient's GP or specialist is the structure, that is named.
GLP-1 effects often require ongoing use to maintain. Where stopping is appropriate — side-effects, life context, planned pregnancy, change in clinical picture — the discontinuation is planned, not abrupt. Rebound effects are anticipated rather than left as a surprise.
When GLP-1 medication is the right tool for the right picture, the metabolic picture moves. Glycaemic control improves where that is the indication. Weight changes occur, often substantially, where that is the indication. Cardiovascular risk markers shift where that is the indication. These changes are measurable and documented, not promised.
GLP-1s are not a cure for the underlying drivers of the metabolic picture. Diet, movement, sleep, stress and the broader hormonal context still matter and still need to be part of the plan. Where the medication is the right addition, it can do real work. Where it is not, the responsible choice is not to prescribe it.